

Carbohydrate-Functionalized Triazolylidene Iridium Complexes: Hydrogenation Catalysis in Water with Asymmetric Induction

Joseph P. Byrne,^[a, b] Lidia Delgado,^[c] Francesca Paradisi,^[a, c] and Martin Albrecht^{*[a]}

Two sets of carbohydrate-NHC hybrid iridium complexes were synthesised in order to combine properties of carbohydrates and triazolylidene (trz) ligands in organometallic catalysis. One set features a direct trz linkage to the anomeric carbohydrate carbon, while the second set is comprised of an ethyl linker between the two functional units. Deprotection of the carbohydrate afforded hybrid complexes that efficiently catalyse the direct hydrogenation of ketones in water. The catalytic activity

of the hybrid complexes was influenced by the pH of the aqueous medium and surpassed the activity of carbohydrate-free or acetyl-protected analogues (> 90% vs 13% yield). While no enantiomeric induction was observed for the ethyl-linked hybrids, a moderate enantiomeric excess (*ee*) was induced by the directly linked systems. Moreover, these carbohydrate-trz hybrid complexes displayed mixed inhibitory activity towards a glycosidase from *H. orenii* that contain a glucose binding site.

Introduction

Carbohydrates constitute an attractive class of compounds for the functionalization of homogeneous catalysts since they impart high water solubility and offer a natural and highly diverse pool for introducing chirality. Remarkably carbohydrates are considerably underexploited in catalysis when compared to other natural chiral pools such as amino acids.^[1,2] Pioneering work involving carbohydrate incorporation into phosphine and phosphinite ligands has demonstrated, however, promisingly high enantioselectivities in catalytic olefin hydrogenation.^[3–10]

Carbohydrate functionalisation of NHC ligands has been developed only recently,^[11] with the majority of research thus far focused towards imidazolylidene ligands and their saturated analogues. Carbohydrate–NHC hybrid complexes have shown anticancer activity,^[12] and catalytic activity in Ru-catalysed olefin metathesis reactions,^[13] Ir-catalysed alcohol and amine oxidation,^[14] and Pd-catalysed Suzuki-Miyaura coupling,^[15–17] as well as in Rh-catalysed carbohydrate-directed asymmetric hydrosilylation of ketones.^[18,19] Notably, these applications involved fully protected carbohydrate derivatives, and only in Suzuki-Miyaura coupling, in situ deprotection under catalytic conditions has been assumed.^[16,17] Our group recently demonstrated that carbohydrate-trz iridium complexes (trz = 1,2,3-triazol-5-ylidene) were sufficiently robust to be deprotected at the carbohydrate site, and that deprotection significantly enhanced the catalytic activity in alcohol and amine oxidation.^[14,20]


The installation of deprotected carbohydrate functionalities on organometallic complexes offers several opportunities. For example, increased solubility in aqueous media allows for using water as a safe, cheap, and abundant solvent^[21,22] with the potential to regulate activity through pH modifications, although stability of organometallic systems in buffer solutions is not yet commonplace.^[23] These properties paired with sufficiently robust complexes have been exploited to couple organometallic catalysis in tandem with enzymatic transformations,^[24–29] and to build artificial metalloenzymes upon docking of organometallic entities to proteins.^[30–32] Similar applications may emerge from carbohydrate-organometallic hybrid systems, since biological receptors for specific carbohydrate bonding are well known, and indeed, carbohydrate-functionalised triazoles were shown to inhibit the activity of glycosidases.^[33,34]


Here we demonstrate the incorporation of a variety of carbohydrate motifs into Ir-triazolylidene complexes, and their marked impact on catalytic ketone hydrogenation catalysis,


[a] Dr. J. P. Byrne, Prof. F. Paradisi, Prof. M. Albrecht
Departement für Chemie
Biochemie und Pharmazie
Universität Bern
Freiestrasse 3
3012 Bern (Switzerland)
E-mail: martin.albrecht@unibe.ch
Homepage: <https://albrecht.dcbp.unibe.ch>

[b] Dr. J. P. Byrne
Present address
School of Chemistry
National University of Ireland Galway
University Road
Galway H91 TK33 (Ireland)

[c] L. Delgado, Prof. F. Paradisi
School of Chemistry
University of Nottingham
University Park
Nottingham NG7 2RD (UK)

 Supporting information for this article is available on the WWW under <https://doi.org/10.1002/cctc.202200086>

 This publication is part of a joint Special Collection with EurJOC on "Carbohydrate Chemistry". Please check the ChemCatChem homepage for more articles in the collection.

 © 2022 The Authors. ChemCatChem published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

both in terms of activity as well as stereoselectivity. Specifically, the anomeric position was identified to be key for inducing *S*- vs *R*-enantio-preference of the catalyst. Furthermore, bonding of the carbohydrate-trz hybrid complexes to glucose hydrolase was probed to establish the impact of the protein on catalysis.

Results and Discussion

Synthesis of carbohydrate–triazolylidene iridium complexes.


Carbohydrate-functionalised triazoles **1** were prepared from phenylacetylene via copper-catalysed alkyne azide cycloaddition (CAAC) of the corresponding glucose-, galactose, and mannose-azides,^[35–37] respectively (Scheme 1). Analogous triazoles **2** with an ethylene spacer between the triazole heterocycle and the carbohydrate unit were synthesized from the corresponding azidoethyl glycopyranosides, which were available via glycosylation of penta-*O*-acetylglycopyranose with bromoethanol and subsequent nucleophilic substitution with NaN_3 .^[38–40] All compounds **1–2** were obtained in good yields (41–78 %).^[12,14,41]

A characteristic singlet at *ca.* 7.9 ppm in each ^1H NMR spectrum confirmed formation of the triazole heterocycle. In all compounds, the triazole displayed a single set of ^1H NMR resonances, confirming that the products did not undergo anomersation. Specifically, the anomeric pair **1 α Man** and **1 β Man**, display different ^1H NMR spectra, with distinct coupling constants of the doublet resonance for the anomeric proton of 2.6 Hz (at 6.07 ppm) and 1.4 Hz (at 6.19 ppm), respectively. The resonances arising from the anomeric protons in triazoles **2** were significantly less deshielded than for **1** and, appeared around δ_{H} 4.5 with a $^3J_{\text{H,H}}=7.8$ Hz coupling for **2 α Glc** and

2 α Gal, and 1.6 Hz for **2 β Man**. Triazole **1 α Gal** was deprotected in excellent yields under Zémpfen conditions (SI),^[33] but attempts to subsequently obtain the corresponding triazolium salt has failed in our hands. Protecting groups were therefore retained for the triazole alkylation and metalation steps.

Near-quantitative alkylation of **1–2** was achieved with $[\text{Me}_3\text{O}]\text{BF}_4$ in CH_2Cl_2 and confirmed by a diagnostic 0.5 ppm downfield shift of the $\text{C}_{\text{trz}}\text{H}$ resonance in the ^1H NMR spectrum of the triazolium salt **3** and **4** as well as by HRMS (ESI+) analysis. Reaction of **3–4** with Ag_2O and transmetalation with $[\text{IrCl}_2(\text{Cp}^*)]_2$ afforded acetate-protected iridium(III) NHC complexes **5–6** in moderate yield (30–48%) after flash chromatography purification. These complexes were characterised by the absence of any downfield resonance in the ^1H NMR spectrum and a diagnostic singlet at *ca.* 1.5 ppm corresponding to the Cp^* ligand. In **5 α Man** and **5 β Man**, the ^1H NMR resonances of the anomeric proton were broadened and also significantly deshielded by *ca.* 1 ppm with respect to **3 α Man** and **3 β Man**, indicating electronic perturbation of this site upon metal coordination, similar to **5 β Glc** and **5 β Gal**.^[14] By contrast, the resonances for the anomeric proton were essentially unchanged for **6** containing an ethylene spacer between the triazolylidene and carbohydrate moieties (δ_{H} 4.69–4.84), suggesting no electronic interaction between the carbohydrate and the Ir–triazolylidene unit.

Exposure of the complexes to methanolic NaOMe , *i.e.* typical acetyl deprotection conditions (*vide supra*), led to decomposition of iridium complexes **5**. Since triazolylidene iridium complexes are generally very stable under acidic conditions,^[42] the acetyl protecting groups in complexes **5–6** were successfully removed with 0.5 M methanolic HCl .^[14] Subsequent precipitation yielded the iridium complexes in



Scheme 1. Synthesis of carbohydrate-functionalized triazolylidene iridium complexes **7** and **8** and crystal structures of **5 β Glc** and **7 β Gal**. (50% probability, hydrogen atoms and CH_3OH molecules co-crystallised with **7 β Gal** omitted for clarity).

good (**7**) to modest (**8**) yields as yellow solids that are air- and moisture stable for several months. The ^1H NMR spectra (CD_3OD) of all deprotected iridium complexes contained a single set of resonances, indicating that epimerization at the anomeric position does not occur under these deprotection conditions. All iridium complexes were analysed by a characteristic atomic mass corresponding to the $[\text{M}-\text{Cl}]^+$ ion by HRMS (ESI+). Moreover, the structure of complex **7 β Gal** was analysed by X-ray diffraction on single crystals grown upon diffusion of Et_2O into CH_3OH solution of the complex. The molecular structure confirms the β -configuration and chair conformation of the carbohydrate entity (Scheme 1). As expected for unprotected carbohydrates, the structure features a series of hydrogen bonding interactions between adjacent galactosyl units as well as to co-crystallized MeOH molecules (SI). No intramolecular hydrogen bonding was identified in the solid state. Bonding geometry about the iridium centre does not deviate significantly from related complex such as **7 β Glc**,^[14] or related complexes containing a simple triazolylidene ligand.^[42]

Interaction of **7 β Gal with molecular hydrogen.** In view of catalytic applications of these iridium complexes, their reactivity towards hydrogen was probed in aqueous solution ($\text{H}_2\text{O}/\text{D}_2\text{O}$ 9:1, 40°C). Exposure of **7 β Gal** to H_2 induced a notable colour change from pale yellow to dark pink within 15 minutes. Analysis by ^1H NMR spectroscopy revealed formation of a new complex which was characterized by a downfield shifted resonance for the $\text{Cp}-\text{CH}_3$ groups ($\Delta\delta$ ca. 1 ppm, Figure S.4a–b) and a broad resonance at $\delta_{\text{H}} = -12.8$ integrating for two hydrogens. The spin lattice relaxation time of this latter high-field resonance, $T_1 < 85\text{ ms}$,^[43] suggests the formation of non-classical hydrides and a $\text{Ir}-(\text{H}_2)$ complex rather than a classical dihydride.^[44,45] This species was stable in solution under ambient conditions for several hours. When analogous experiments were carried out in D_2O solution, the same shift in the Cp^* signal was observed, but no high-field resonance was detectable. Instead, deuterium incorporation into the phenyl group of the triazolylidene ligand was observed by the disappearance of ^1H resonances in the aromatic region of the ^1H NMR spectrum (Figure S.4c–d). These data indicate H/D exchange of the hydride complex with solvent water and reversible cyclo-metallation of the phenyl group under these conditions.^[46,47] We note that water is crucial as a solvent since no hydrogen complex was observed when the reaction was carried out in CH_2Cl_2 , EtOH , or MeOH . The carbohydrate functionality is obviously assisting in ensuring water solubility of the iridium complexes, though related unfunctionalized triazolylidene iridium complexes similarly form hydrides.^[48] The ability of **7 β Gal** to bind and activate hydrogen under atmospheric dihydrogen pressures prompts the use of this class of carbohydrate-functionalised NHC complex for application in direct hydrogenation catalysis in aqueous media.

Ketone hydrogenation catalysis in aqueous conditions. The catalytic activity of iridium complex **7 β Gal** in ketone hydrogenation was assessed by saturating an aqueous solution at various pH with hydrogen gas for 15 minutes, *i.e.*, conditions that induce formation of the dihydrogen complex (*vide supra*). Subsequent addition of acetophenone as model substrate

induced quantitative conversion to 1-phenylethanol in less than 3 h (40°C , 1 mol% **7 β Gal**). Working in aqueous media offers opportunities to optimize the catalytic activity via pH modulation. Therefore, catalytic runs of **7 β Gal** were conducted at different pH values using various buffer media (Table 1). Under neutral, and even more so under basic conditions, maximum yields were low, reaching only 18% and 35% yield at pH 8.0 and 7.4, respectively (entries 1,2). Precipitation of a yellow solid was also observed at basic pH after a few hours, tentatively attributed to the formation of insoluble hydroxide complexes. The catalytic performance improved considerably at acidic pH. At pH 5.8, yields reached 74% (entry 3), while further acidification to pH 5.0 gave 94% yield in 3 h and quantitative conversion after 4 h (entry 4). At pH 3.0, quantitative hydrogenation with **7 β Gal** was accomplished already within 2 h (entry 5, Figure S5). Under these conditions, also lower catalyst loadings were active, though at 0.1 mol% **7 β Gal**, conversions were incomplete even after 24 h and gave a maximum turnover number of 360. These data reveal a clear relationship between pH and both the reaction rate and final product yield, consistent with observations by Ogo *et al.*^[49] with Ru-catalysed transfer hydrogenation. This behaviour may be rationalised by an increased stability of the hydride complex combined with substrate activation through proton bonding by the carbonyl group.^[22,49]

While the well-defined stereochemistry of carbohydrates may induce asymmetric catalysis,^[3,18,50–53] hydrogenation with **7 β Gal** induced only a modest enantiomeric excess towards S-1-phenylethanol with slight variation upon pH modification. We note that the type of buffer, has a more significant impact on the modest but consistent enantiomeric enrichment of the 1-phenylethanol than the pH. Highest asymmetric induction (30% ee) was observed in citrate buffer, while unbuffered conditions (26% ee) were less effective, followed by phosphate (20% ee) and HEPES buffer (15% ee). This dependence suggests that the hydride stabilization by the buffer may be critical for enantio-discrimination of the substrate.

The impact of the carbohydrate functionality was probed under the optimised conditions, *viz.* citrate buffer at pH 3.0. The

Table 1. Catalytic acetophenone hydrogenation in aqueous solution buffered at various pH.^[a]

Entry	Complex	pH	Buffer (50 mM)	Yield ^[b] [3 h; %]	e.e. [%] ^[c]
1	7βGal	8.0	Phosphate	18 ^d	20 (S)
2	7βGal	7.4	HEPES	35	15 (S)
3	7βGal	5.8	Phosphate	74	21 (S)
4	7βGal	5.0	Citrate	94	32 (S)
5	7βGal	3.0	Citrate	> 98	30 (S)

[a] General conditions: acetophenone (0.1 mmol), Ir complex (1 μmol , 1 mol%), aqueous buffer (1.0 mL); [b] determined by LCMS with phenol as internal standard; [c] determined by chiral GC; [d] yellow precipitate formed.

catalytic activity of **7βGlc**, **7βMan** and **7αMan** were highly similar to that of **7βGal** and reached >90% conversion within 2 h (Table 2 and Figure S6). Like **7βGal**, **7βGlc** and **7βMan** led to preferential formation of the *S*-enantiomer with 34% and 46%

Entry	Complex	Yield [2 h, %] ^[b]	e.e. [%] ^[c]
1	7βGal	98 (94)	30 (<i>S</i>)
2	7βGlc	99 (94)	34 (<i>S</i>)
3	7βMan	90 (86)	46 (<i>S</i>)
4	7αMan	95 (99)	39 (<i>R</i>)
5	9	13 (18)	<4
6	5βGal	70 (63)	45 (<i>S</i>)
7	5βGlc	70 (66)	45 (<i>S</i>)
8	5βMan	55 (69)	34 (<i>S</i>)
9	5αMan	55 (65)	6 (<i>S</i>)
10	8βGal	47 (40)	<4
11	8βGlc	59 (50)	<4
12	8αMan	47 (52)	<4

[a] general conditions: acetophenone (0.1 mmol), Ir complex (1 μmol, 1 mol%), citrate buffer (1.0 mL, 50 mM, pH 3.0), H₂ (1 atm.), 40 °C; [b] yields determined by HPLC relative to phenol as internal standard (in parentheses yields determined by ¹H NMR spectroscopy in CDCl₃ after product extraction, relative to anisole as internal standard); [c] determined by chiral GC.





Figure 1. Structure of simple triazolylidene complex **9**.

ee, respectively (entries 1–3). The same selectivity of **7βGal** and **7βGlc** suggests that the stereochemistry of the remote C-4 hydroxy group has negligible impact on the chirality transfer, while inversion at C-2 increases the asymmetric induction (**7βGal** vs **7βMan**). Remarkably, **7αMan** showed the opposite enantio-preference and favours the *R*-enantiomer (39% *ee*; entry 4). This outcome underscores that the NHC-linked carbohydrate scaffold is playing a pivotal role in substrate orientation for asymmetric hydrogen transfer, and that the anomeric configuration is decisive for *S*- vs *R*-preference.

A set of control experiments underpinned the pivotal role of the carbohydrate entity on both catalytic activity and asymmetric induction. Thus, catalytic hydrogenation reaction with **9**, a model iridium complex without carbohydrate functionality (Figure 1), gave very low yield and produced racemic product (Table 2, entry 5). Likewise, complexes **5** containing acetyl-protected carbohydrate units were considerably less active than the analogues with free carbohydrates and reached only 55–70% yield after 2 h (entries 6–9). Remarkably, the acetyl-protected complexes **5βGal** and **5βGlc** induce a higher enantiomeric excess (45%) than their deprotected analogues, while the effect is inverted for the mannose derivatives **5αMan** and **5βMan**. Furthermore, all protected carbohydrate-triazolylidene complexes showed a preference for the *S*-enantiomer, irrespective of the anomeric configuration.

In line with these trends, complexes **8** possessing an ethylene spacer between the deprotected carbohydrate and NHC units gave moderate yields of 47–59% in 2 h and no significant asymmetric induction (entries 10–12). The lack of *ee* is in agreement with the absence of any significant interaction between the carbohydrate and the triazolylidene entities as deduced also by NMR spectroscopy (*vide supra*).

A small substrate scope was carried out with **7βGal** as catalyst precursor (Scheme 2a). Acetophenones substituted



Scheme 2. Products formed by hydrogenation of various substrates. General reaction conditions: substrate (0.1 mmol), **7βGal** (1 μmol, 1 mol%), 1 atm. H₂, 40 °C, citrate buffer (1.0 mL, 50 mM, pH 3.0); yields determined by ¹H NMR spectroscopy with anisole as internal standard after 2 h unless stated otherwise.

with electron-withdrawing nitro and electron-donating methoxy groups were converted with high yields, while an amine substituent impeded catalysis considerably. Cyclohexanone as a representative of aliphatic ketones and also bromobenzaldehyde were reduced under these conditions. Stilbene was inert, suggesting that olefins are not hydrogenated. However, activated olefins in α,β -unsaturated ketones are converted as demonstrated with cinammyl ketone (Scheme 2b). Hydrogenation is considerably slower than with acetophenone with 38% conversion after 2 h and some selectivity towards the saturated ketone intermediate. This selectivity may be a consequence of predominant olefin reduction or efficient double bond migration.^[54] Extension of the reaction time to 16 h yielded predominantly the fully reduced product.

Interactions of iridium complexes with *H. orenii* β -glucosidase (GH1) enzyme. Further tailoring of activity and selectivity was anticipated by embedding the catalytically active site within a biological scaffold. Specifically, we aimed at using the carbohydrate functionality in complexes 7–8 as anchoring group for interaction with β -glucosidase (GH1) enzyme from *H. orenii*, a thermophilic glycosidase containing an active site that is pre-organised to bind and hydrolyse O-linked β -glycopyranosides.^[55]

Binding of various concentrations of complexes 7–8 was probed by monitoring the enzymatic rate of hydrolysis of *p*-nitrophenyl glucoside by a UV-Vis assay. Essentially complete inhibition (90–98%) was observed with all complexes at 0.5 mM concentration (Figure S43). Notably, model complex 9 without a carbohydrate functionality showed a similar level of inhibition, indicating that the loss of enzymatic activity is not limited to the competitive binding of the carbohydrate unit of complexes 7–8 to the GH1 active site.

Inhibition kinetic experiments were carried out for each complex, analysing the activity of the GH1 enzyme in the presence of 0.05 mM of each iridium complex 7–9. Variations in the reaction parameters with respect to the uninhibited enzyme (Table S2, ESI) indicate that all the complexes behave as ‘mixed inhibitors’, demonstrating a combination of competitive and non-competitive inhibition processes. Allosteric binding at sites other than the active carbohydrate-binding site is also occurring. Modelled as mixed inhibitors, dissociation constants for both processes were calculated. As expected for a β -glucosidase, the glucose-derived molecules, **7 β Glc** and **8 β Glc** ($K_c = 2.9(5)$ and $3.4(2)$ μ M, respectively), have higher competitive affinity for the enzyme than the other examples, with **7 β Glc** being *ca.* tenfold higher than the uncompetitive affinity.

Catalytic hydrogenation experiments with **7 β Gal** in the presence of excess GH1 showed no detectable catalytic activity on acetophenone, suggesting that the lack of selective binding prevents these hybrid complexes from assembling into effective artificial metalloenzymes, and the catalyst active site is hindered. Indeed, in catalytic runs with 1 mM solutions of **7 β Gal** and **7 β Glc**, conversion of acetophenone was impacted already in the presence of only 0.3 μ M GH1 at pH 7.4 (HEPES 50 mM),^[56] achieving about 20% and 15% yield, respectively, *i.e.*, half of the performance recorded in the absence of the enzyme (*cf.* Table 1). Interestingly, catalytic runs in the presence of non-

carbohydrate-binding protein BSA also stalled the activity of **7 β Gal**, indicating a more general role of proteins to hinder this particular reaction. While catalysts 7–8 are bio-compatible and operate under physiologically relevant conditions in aqueous buffer solutions, translation of catalytic activity to biocatalysis through coupling with a protein scaffold still presents a significant challenge. In order to successfully exploit this bio-recognition, stronger and more specific protein-carbohydrate interactions with the carbohydrate-organometallic hybrid scaffold are required, such as, for example, those exhibited by lectins (e.g. Concanavalin A).^[57] Multivalency, where multiple carbohydrate units are presented by a structure, are also well known to increase affinity of compounds for protein carbohydrate-receptor sites.^[58] Moreover, variation of the iridium catalytic site, *e.g.* by chelate bonding might shield it from the protein environment to a greater extent and reduce inhibitive interactions.

Conclusions

Carbohydrate-functionalised triazolylidene NHC iridium complexes are efficient pre-catalysts for ketone hydrogenation under mild aqueous conditions and low hydrogen pressures. They significantly outperform carbohydrate-free analogues and acetyl-protected analogues. Direct linkage of the carbohydrate motif to the NHC imparts much higher catalytic benefits compared to ethylene linked more remote carbohydrate trz hybrids. Under optimized conditions at low pH (citrate buffer at pH 3.0), these carbohydrate NHC systems gave essentially quantitative yields for hydrogenation of acetophenone within 2 h. While the carbohydrate entity induced only moderate enantiomeric enrichment up to \sim 50%, the enantioselectivity of the catalyst directly correlates with the stereochemistry at the anomeric carbohydrate position, which offers rational guidelines for further catalyst optimisations. Complexes 7–9 completely inhibited activity of glycosidase enzyme GH1 (*H. orenii*), acting as mixed inhibitors. Kinetic data showed that the glucose-derivatives has the highest competitive binding affinity for GH1, but hydrogenation catalysis was completely impeded by enzyme interactions. More efficient anchoring of the hybrid in the active site may provide a further approach to modulate and increase the catalytic activity and selectivity of these hybrid systems.

Experimental Section

General experimental details. 1- α -azido-2,3,4,6-tetra-O-acetylmannopyranose was prepared by reaction of penta-O-acetylmannopyranose with TMSN₃ and SnCl₄^[36] while the β -anomer was prepared *via* a glycosyl iodide.^[37] 1-azidoethyl-2,3,4,6-tetra-O-acetylglycopyranosides,^[38–40] **1Glc**,^[14] **1Gal**,^[14] **1 α Man**,^[41] **2Man**,^[41] **4Glc**,^[14] **4Gal**,^[14] [IrCl₂Cp*]₂,^[59] **5 β Glc**,^[14] **5 β Gal**,^[14] **7 β Gal**,^[14] **7 β Glc**^[14] and **9**^[42] were prepared as described previously. Ag₂O was used after regeneration by heating to $>160^\circ\text{C}$ under vacuum. Dry, degassed solvents were obtained by filtering over columns of dried aluminium oxide under a positive pressure of argon. Other reagents were obtained from commercial suppliers and used as received.

NMR spectra were recorded on Bruker spectrometer operating at room temperature. Chemical shifts (δ in ppm, J in Hz) were referenced to residual solvent resonances and are reported downfield from SiMe₄. High resolution mass spectrometry and elemental analysis were performed by the Analytical Research Services at University of Bern.

Gas chromatography (GC) was performed on an Agilent 7820 A GC System using a CP-Chirasil-DEXC8 column (25 mm × 0.25 mm × 0.25 μ m) as stationary phase. LC analysis was carried out with an Agilent 1260 HPLC system, equipped with a reverse phase XBridge C18 (3.5 μ m, 2.1 mm × 30 mm) column, running a gradient method with 0.01 % aqueous ammonia and acetonitrile.

Enzyme activity and inhibition assays. In a 96-well plate, 10 μ L of enzyme solution, 90 μ L of inhibitor solution and 200 μ L of *p*-nitrophenyl glucoside solution were added together (to give final concentrations of [*p*-nitrophenyl glucoside] = 10 mM, [HEPES] = 50 mM, pH 7.4). Immediately upon mixing, the assay was begun and formation of *p*-nitrophenol monitored by measuring the formation of the absorbance at 420 nm over 10 minutes. Specific activity (U/mg) was expressed as μ mol of product formed per minute per mg of protein. For inhibition studies [inhibitor] = 0–0.5 mM was used. For inhibition kinetics final concentration of [inhibitor] = 0.05 mM was used.

Catalytic hydrogenation. A 1.0 mM stock solution of the iridium complex was made up in aqueous buffer. 1.0 mL of this was transferred to a 10-mL round bottomed flask, before fitting with a rubber septum. The solution was saturated with H₂ for 15 minutes at 40 °C. Acetophenone (12 μ L, 0.10 mmol) was added and the reaction allowed to proceed under H₂ atmosphere.

To monitor the reaction by LC analysis, phenol was added as an internal standard before addition of ketone substrate, and the reaction sampled regularly by syringe. Chiral GC analysis samples were prepared from reactions without phenol and diluted in 2-propanol. In order to determine yield spectroscopically by ¹H NMR: after 2 h anisole (12 μ L, 0.11 mmol), as internal standard, and NaCl (0.3 g) were added, and the reaction mixture extracted (0.5 mL × 3) into CDCl₃.

Formation of iridium hydride species. 7 β Gal (5.0 mg, 0.007 mmol) was dissolved in a 9:1 mixture of deionized H₂O and D₂O and was bubbled with H₂ for 15 minutes at 40 °C. The ¹H NMR spectrum was measured at various temperatures under ambient conditions.

General synthesis of triazoles. The relevant protected azide precursor (1 equiv.), CuSO₄ · 5H₂O (0.4 equiv.) and sodium ascorbate (1 equiv.) were dissolved in aqueous *tert*-butanol solution (1:1 mixture). To this, phenyl acetylene (1 equiv.) was added and (a) stirred at room temperature for 3 days, or (b) heated by microwave irradiation to 100 °C for 6 hours. Reaction mixture was extracted into CH₂Cl₂ and washed with NH₄Cl(aq) (×3), water (×2) and brine (×2), dried over Na₂SO₄, filtered and concentrated under reduced pressure, yielding the triazole as a white or off-white solid. For 2Glc, 2Gal and 2Man, a precipitation from Et₂O was necessary to purify the compound.

1 β Man. According to the general procedure, 1- β -azido-2,3,4,6-tetra-*O*-acetylmannopyranose (0.270 g, 0.73 mmol), CuSO₄ · 5H₂O (0.073 g, 0.30 mmol), sodium ascorbate (0.146 g, 0.72 mmol) and phenylacetylene (0.08 mL, 0.73 mmol) were reacted. The crude solid was triturated with CH₃OH and filtered, yielding 1 β Man (0.240 g, 0.50 mmol, 70%). Anal. calc. for C₂₂H₂₅N₃O₉ · CH₃OH (507.498 g/mol), C 54.43, H 5.76, N 8.28%. Found C 54.18, H 6.29, N 8.31%; HRMS (ESI+) Calculated for C₂₂H₂₆N₃O₉⁺ [M + H]⁺ m/z = 476.1664. Found m/z = 476.1650; ¹H NMR (400 MHz, CDCl₃): δ = 2.00 (s, 3H, OC(O)CH₃), 2.05–2.19 (m, 9H, 3 × OC(O)CH₃), 4.00 (ddd, 1H, ³J_{H,H} = 10.0,

6.2, 2.3 Hz, mannosyl C⁵H), 4.23 (dd, 1H, ³J_{H,H} = 2.3 Hz, ²J_{H,H} = 12.5 Hz, mannosyl C⁶HH), 4.37 (dd, 1H, ³J_{H,H} = 6.1 Hz, ²J_{H,H} = 12.5 Hz, mannosyl C⁶HH), 5.31 (dd, 1H, ³J_{H,H} = 10.0, 3.1 Hz, mannosyl C³H), 5.38 (t, 1H, ³J_{H,H} = 10.0 Hz, mannosyl C⁴H), 5.80 (dd, 1H, ³J_{H,H} = 3.1, 1.4 Hz, mannosyl C²H), 6.19 (d, 1H, ³J_{H,H} = 1.4 Hz, mannosyl C¹H), 7.29–7.39 (m, 1H, C_{trz}H), 7.40–7.60 (m, 2H, C_{ph}H), 7.74–7.86 (m, 2H, C_{ph}H), 7.99 (s, 1H, C_{trz}H); ¹³C NMR (100 MHz, CDCl₃): δ = 20.5, 20.6, 20.66, 20.74, (4 × OC(O)CH₃), 62.3 (mannosyl C⁶H₂), 65.0 (mannosyl C¹H), 68.9 (mannosyl C²H), 70.8 mannosyl C³H), 75.8, (mannosyl C⁵H), 84.8, (mannosyl C¹H), 118.4, (C_{trz}H), 125.8, 128.5, 128.9 (3 × C_{ph}H), 130.1 (C_{ph}–trz), 147.8 (C_{trz}–Ph), 168.9, 169.6, 169.7, 170.5 (4 × C=O)

2 β Glc. According to the general procedure, 1-azidoethyl-2,3,4,6-tetra-*O*-acetylglucopyranoside (0.950 g, 2.30 mmol), CuSO₄ · 5H₂O (0.230 g, 0.92 mmol), sodium ascorbate (0.455 g, 2.30 mmol) and phenylacetylene (0.25 mL, 2.30 mmol) were reacted, yielding 2 β Glc (0.680 g, 1.27 mmol, 55%). Anal. calc. for C₂₄H₂₉N₃O₁₀ · 0.5(H₂O) · 0.5((C₂H₅)₂O) (519.509 g/mol), C 55.22, H 6.24, N 7.43%. Found C 55.48, H 6.75, N 7.54%; HRMS (ESI+) Calculated for C₂₄H₂₉N₃O₁₀Na⁺ [M + Na]⁺ m/z = 542.1751. Found m/z = 542.1727; ¹H NMR (300 MHz, CDCl₃): δ = 1.72, 1.98, 2.01, 2.07 (4 × s, 3H, OC(O)CH₃), 3.69 (ddd, 1H, ³J_{H,H} = 9.5, 4.5, 2.5 Hz, glucosyl C⁵H), 3.91 (td, 1H, ³J_{H,H} = 2.5 Hz, ²J_{H,H} = 9.5 Hz, ethylene CHH), 4.13 (dd, 1H, ³J_{H,H} = 2.5 Hz, ²J_{H,H} = 12.4 Hz, glucosyl C⁶HH), 4.21–4.33 (m, 2H, glucosyl C⁶HH and ethylene CHH), 4.46 (d, 1H, ³J_{H,H} = 7.8 Hz, glucosyl C¹H), 4.49–4.75 (m, 2H, ethylene CH₂), 4.97–5.25 (m, 3H, glucosyl C²H, C³H, C⁴H), 7.27–7.36 (m, 1H, C_{ph}H), 7.37–7.49 (m, 2H, C_{ph}H), 7.80–7.91 (m, 3H, C_{ph}H and C_{trz}H); ¹³C NMR (75 MHz, CD₃OD): δ = 20.4, 20.59, 20.60, 20.7 (4 × OC(O)CH₃), 50.1 (ethylene CH₂), 61.7 (glucosyl C⁶H₂), 67.9 (ethylene CH₂), 68.2 (glucosyl C⁴H), 70.9 (glucosyl C²H), 72.0 (glucosyl C³H), 72.4 (glucosyl C⁵H), 100.5 (glucosyl C¹H), 121.4 (C_{trz}H), 125.7, 128.2, 128.8, 130.5 (4 × C_{ph}), 147.6 (C_{trz}–Ph), 169.4, 169.5, 170.1, 170.6 (4 × C=O).

2 β Gal. According to the general procedure, 1-azidoethyl-2,3,4,6-tetra-*O*-acetylgalactopyranoside (2.03 g, 4.87 mmol), CuSO₄ · 5H₂O (0.486 g, 1.95 mmol), sodium ascorbate (0.965 g, 4.87 mmol) and phenylacetylene (0.53 mL, 4.87 mmol) were reacted, yielding 2 β Gal (1.100 g, 2.12 mmol, 43%). Anal. calc. for C₂₄H₂₉N₃O₁₀ · 0.5(H₂O) · 0.5((C₂H₅)₂O) (519.509 g/mol), C 55.22, H 6.24, N 7.43%. Found C 55.45, H 6.66, N 7.30%; HRMS (ESI+) Calculated for C₂₄H₃₀N₃O₁₀⁺ [M + H]⁺ m/z = 520.1926. Found m/z = 520.1937; ¹H NMR (300 MHz, CDCl₃): δ = 1.70, 1.95, 2.04, 2.14 (4 × s, 3H, OC(O)CH₃), 3.84–3.97 (m, 2H, galactosyl C⁵H and ethylene CHH), 4.01–4.20 (m, 2H, galactosyl C⁶H₂), 4.29 (ddd, 1H, ³J_{H,H} = 4.2, 3.0 Hz, ²J_{H,H} = 10.1 Hz, ethylene CHH), 4.43 (d, 1H, J = 7.9 Hz, galactosyl C¹H), 4.54 (ddd, 1H, ³J_{H,H} = 9.3, 3.0 Hz, ²J_{H,H} = 14.5 Hz, ethylene CHH), 4.69 (ddd, 1H, ³J_{H,H} = 4.2, 3.0 Hz, ²J_{H,H} = 14.5 Hz, ethylene CHH), 4.95 (dd, 1H, ³J_{H,H} = 10.5, 3.5 Hz, galactosyl C³H), 5.21 (dd, 1H, ³J_{H,H} = 10.5, 7.9 Hz, galactosyl C²H), 5.38 (dd, 1H, ³J_{H,H} = 3.5, 1.1 Hz, galactosyl C⁴H), 7.27–7.36 (m, 1H, C_{ph}H), 7.38–7.48 (m, 2H, C_{ph}H), 7.79–7.93 (m, 3H, 2 × C_{ph}H and C_{trz}H); ¹³C NMR (75 MHz, CD₃OD): δ = 20.47, 20.54, 20.66, 20.70 (4 × OC(O)CH₃), 50.1 (ethylene CH₂), 61.2 (galactosyl C⁶H₂), 66.9 (galactosyl C⁴H), 67.8 (ethylene CH₂), 68.5 (galactosyl C²H), 70.6 (galactosyl C³H), 70.8 (galactosyl C⁵H), 100.9 (galactosyl C¹H), 121.6 (C_{trz}H), 125.7, 128.1, 128.8, 130.5 (4 × C_{ph}), 147.6 (C_{trz}–Ph), 169.7, 170.0, 170.2, 170.4 (4 × C=O).

General synthesis of triazolium salts. The relevant triazole (1 equiv.) and Meerwein's reagent (Me₃OBf₄, 1.1 equiv.) were suspended in dry CH₂Cl₂ (50 mL) and stirred at room temperature for 18 hours. Reaction was quenched with CH₃OH (0.5 mL) and concentrated under reduced pressure, yielding the product, which could be further purified by dissolving in a minimum of CH₂Cl₂ and addition of copious diethyl ether, causing triazolium salts to precipitate as white solid in near-quantitative yields. These compounds were hygroscopic.

3 α Man. According to the general procedure, **1 α Man** (1.238 g, 2.60 mmol) and Meerwein's reagent (0.414 g, 2.80 mmol) were reacted, yielding **3 α Man** (1.550 g, quant.). HRMS (ESI⁺): Calculated for C₂₃H₂₈N₃O₉⁺ [M-BF₄]⁺ m/z =490.1820. Found m/z =490.1799; ¹H NMR (300 MHz, CDCl₃): δ =2.04–2.12 (m, 9H, 3 \times OC(O)CH₃), 2.18 (s, 3H, OC(O)CH₃ [overlaps with acetone peak]), 4.07–4.56 (m, 6H, N-CH₃, mannosyl C⁶H₂, C⁵H), 5.35 (t, 1H, ³J_{H,H}=8.0 Hz, mannosyl C⁴H), 5.56 (dd, 1H, ³J_{H,H}=8.0, 3.5 Hz, mannosyl C³H), 6.04 (t, 1H, J =3.5 Hz, mannosyl C²H), 6.47 (d, 1H, ³J_{H,H}=3.5 Hz, mannosyl C¹H), 7.51–7.70 (m, 5H, C_{ph}H), 8.57 (s, 1H, C_{trz}H); ¹³C NMR (75 MHz, CDCl₃): δ =20.53, 20.55, 20.6, 20.69 (4 \times OC(O)CH₃), 39.2 (N-CH₃), 61.2 (mannosyl C⁶H₂), 65.2 (mannosyl C⁴H), 66.6 (mannosyl C³H), 68.4 (mannosyl C²H), 73.4 (mannosyl C⁵H), 87.4 (mannosyl C¹H), 121.5 (C_{ph}-trz), 128.4 (C_{trz}H), 129.6, 129.7, 132.1 (3 \times C_{ph}H), 144.5 (C_{trz}-Ph), 169.64, 169.65, 170.0, 170.9 (4 \times C=O).

3 β Man. According to the general procedure, **1 β Man** (0.240 g, 0.46 mmol) and Meerwein's reagent (0.071 g, 0.48 mmol) were reacted, yielding **3 β Man** (0.285 g, quant.). HRMS (ESI⁺): Calculated for C₂₃H₂₈N₃O₉⁺ [M-BF₄]⁺ m/z =490.1820. Found m/z =490.1916; ¹H NMR (300 MHz, CDCl₃): δ =2.01, 2.12, 2.14, 2.16 (4 \times s, 3H, OC(O)CH₃), 4.18–4.38 (m, 6H, N-CH₃, mannosyl C⁵H, C⁶HH), 4.45 (dd, 1H, ³J_{H,H}=5.5 Hz, ²J_{H,H}=12.9 Hz, mannosyl C⁶HH), 5.37–5.55 (m, 2H, mannosyl C³H, C⁴H), 6.04 (app s, 1H, mannosyl C²H), 6.53 (app s, 1H, mannosyl C¹H), 7.54–7.69 (m, 5H, C_{ph}H), 8.51 (s, 1H, C_{trz}H); ¹³C NMR (101 MHz, CDCl₃): δ =20.4, 20.5, 20.6, 20.7 (4 \times OC(O)CH₃), 39.0 (N-CH₃), 61.6 (mannosyl C⁶H₂), 64.6 (mannosyl C⁴H), 67.7 (mannosyl C²H), 70.8 (mannosyl C³H), 75.9 (mannosyl C⁵H), 86.5 (mannosyl C¹H), 121.6 (C_{ph}-trz), 127.5 (C_{trz}H), 129.6, 129.8, 132.2 (3 \times C_{ph}H), 143.6 (C_{trz}-Ph), 169.6, 169.7, 169.8, 170.8 (4 \times C=O).

4 β Glc. According to the general procedure, **2 β Glc** (0.770 g, 1.50 mmol) and Meerwein's reagent (0.244 g, 1.65 mmol) were reacted, yielding **4 β Glc** (0.900 g, 1.12 mmol, 74%). Calculated for C₂₅H₃₂N₃O₁₀⁺ [M-BF₄]⁺ m/z =534.2064. Found m/z =534.2084; ¹H NMR (300 MHz, CD₃OD): δ =1.94, 1.99 (2 \times s, 3H, OC(O)CH₃), 2.02–2.06 (m, 6H, 2 \times OC(O)CH₃), 3.77–3.86 (ddd, 1H, ³J_{H,H}=10.1, 4.4, 2.0 Hz, glucosyl C⁵H), 4.0–94.44 (m, 7H, N-CH₃, glucosyl C⁶H₂, O-CH₂-CH₂N), 4.69 (d, 1H, ³J_{H,H}=7.9 Hz, glucosyl C¹H), 2.82–2.98 (m, 3H, O-CH₂-CH₂N and glucosyl C²H), 5.04 (t, 1H, ³J_{H,H}=9.5 Hz, glucosyl C⁴H), 5.22 (t, 1H, J =9.5 Hz, glucosyl C³H), 7.53–7.72 (m, 5H, C_{ph}H), 8.52 (C_{trz}H); ¹³C NMR (75 MHz, CD₃OD): δ =20.57, 20.62, 20.7, (4 \times OC(O)CH₃ [2 \times overlapping]), 38.4 (N-CH₃), 54.1 (ethylene CH₂), 61.6 (glucosyl C⁶H₂), 66.6 (ethylene CH₂), 68.1 (glucosyl C⁴H), 71.2 (glucosyl C²H), 71.9 (glucosyl C⁵H), 72.5 (glucosyl C³H), 100.6 (glucosyl C¹H), 122.0 (C_{ph}-trz), 129.2 (C_{trz}H), 129.4, 129.8, 132.0 (3 \times C_{ph}H), 143.2 (C_{trz}-Ph), 169.6, 169.9, 170.0, 170.7 (4 \times C=O).

4 β Gal. According to the general procedure, **2 β Gal** (0.535 g, 1.03 mmol) and Meerwein's reagent (0.165 g, 1.10 mmol) were reacted, yielding **4 β Gal** (0.695 g, quant.). Calculated for C₂₅H₃₂N₃O₁₀⁺ [M-BF₄]⁺ m/z =534.2064. Found m/z =534.2070; ¹H NMR (300 MHz, CDCl₃): δ =1.90, 1.95, 2.04, 2.10 (4 \times s, 3H OC(O)CH₃), 3.97 (t, 1H, ³J_{H,H}=6.5 Hz, galactosyl C⁵H), 4.01–16 (m, 2H, galactosyl C⁶H₂), 4.17–4.39 (m, 5H, ethylene CH₂, N-CH₃), 4.62 (d, 1H, ³J_{H,H}=7.6 Hz, galactosyl C¹H), 4.76–4.98 (m, 2H, ethylene CH₂), 5.01 (dd, 1H, ³J_{H,H}=10.4, 3.3 Hz, galactosyl C³H), 5.09 (dd, 1H, ³J_{H,H}=10.4, 7.6 Hz, galactosyl C²H), 5.38 (dd, 1H, ³J_{H,H}=3.3, 1.1 Hz, galactosyl C⁴H), 7.52–7.72 (m, 5H, C_{ph}H), 8.51 (C_{trz}H); ¹³C NMR (75 MHz, CDCl₃): δ =20.5, 20.6, 20.7 (4 \times OC(O)CH₃ [2 \times overlapping]), 38.4 (N-CH₃), 54.1 (ethylene CH₂), 61.2 (galactosyl C⁶H₂), 66.2 (ethylene CH₂), 67.0 (galactosyl C⁴H), 68.7 (galactosyl C²H), 70.5 (galactosyl C³H), 70.9 (galactosyl C⁵H), 100.9 (galactosyl C¹H), 122.1 (C_{ph}-trz), 129.1 (C_{trz}H), 129.4, 129.8, 132.0 (3 \times C_{ph}H), 143.3 (C_{trz}-Ph), 169.9, 170.1, 170.4, 170.6 (4 \times C=O).

4 α Man. According to the general procedure, **2 α Man** (0.720 g, 1.38 mmol) and Meerwein's reagent (0.209 g, 1.41 mmol) were

reacted, yielding **4 α Man** (0.840 g, quant.). Calculated for C₂₅H₃₂N₃O₁₀⁺ [M-BF₄]⁺ m/z =534.2064. Found m/z =534.2069; ¹H NMR (300 MHz, CDCl₃): δ =1.97, 2.02, 2.10, 2.14 (4 \times s, 3H, 4 \times OC(O)CH₃), 3.87–4.02 (m, 1H, mannosyl C⁵H), 4.01–4.37 (m, 8H, N-CH₃, mannosyl C⁶H₂ and ethylene CH₂), 4.84 (d, 1H, ³J_{H,H}=1.8 Hz, mannosyl C¹H), 4.93 (app t, 2H, ethylene CH₂), 5.12 (dd, 1H, ³J_{H,H}=3.0, 1.8 Hz, mannosyl C²H), 5.13–5.34 (m, 2H, mannosyl C²H, C⁴H), 7.51–7.71 (m, 5H, C_{ph}H), 8.67 (s, 1H, C_{trz}H); ¹³C NMR (75 MHz, CDCl₃): δ =20.71, 20.75, 20.9 (4 \times OC(O)CH₃ [2 \times overlapping]), 38.5 (N-CH₃), 53.6 (ethylene CH₂), 62.4 (mannosyl C⁶H₂), 64.6 (ethylene CH₂), 65.8 (mannosyl C⁴H), 68.9 (mannosyl C³H), 69.0 (mannosyl C²H), 69.1 (mannosyl C⁵H), 97.3 (mannosyl C¹H), 121.9 (C_{ph}-trz), 129.0 (C_{trz}-Ph), 129.5, 129.7, 132.0 (3 \times C_{ph}H), 143.7 (C_{trz}-Ph), 169.7, 170.2, 170.3, 170.9 (4 \times C=O).

General synthesis of iridium complexes. The relevant triazolium salt (1 equiv.), Ag₂O (0.5 equiv.) and NMe₄Cl (1 equiv.) were suspended in dry CH₃CN (50 mL) and stirred in darkness at room temperature for 18 hours. Crude ¹H NMR analysis showed disappearance of the resonance associated with the triazolium CH. The reaction mixture was filtered through a bed of celite and concentrated under reduced pressure. The residue was dissolved in dry CH₂Cl₂ and [IrCl₂Cp*]₂ (0.37 equiv.) added. The reaction was stirred in darkness at room temperature for 18 hours, before cooling over an ice bath, filtering through a bed of Celite and concentrating under reduced pressure, yielding a crude orange solid. This was purified by gradient flash chromatography (SiO₂; CH₂Cl₂-(CH₂)₂CO 0 \rightarrow 10%), yielding the product as a yellow solid.

5 α Man. According to the general procedure, **3 α Man** (1.346 g, 2.33 mmol), Ag₂O (0.278 g, 1.20 mmol), NMe₄Cl (0.254 g, 2.33 mmol) and [IrCl₂Cp*]₂ (0.708 g, 0.89 mmol) were reacted, yielding **5 α Man** (0.480 g, 1.07 mmol, 46%). Anal. calc. for C₃₃H₄₂N₃O₉IrCl₂ (887.834 g/mol), C 44.64, H 4.77, N 4.73%. Found C 45.08, H 5.18, N 4.39%; HRMS (ESI⁺) Calculated for C₃₃H₄₂N₃O₉IrCl₂⁺ [M-Cl]⁺ m/z =852.2233. Found m/z =852.2237; ¹H NMR (300 MHz, CDCl₃): δ =1.49 (s, 15H, Cp*), 2.02, 2.08, 2.13, 2.24 (4 \times s, 3H, OC(O)CH₃), 3.88 (s, 3H, N-CH₃), 4.15–4.44 (m, 3H, mannosyl C⁶H₂ and C⁵H), 5.43 (t, 1H, ³J_{H,H}=9.9 Hz, mannosyl C⁴H), 5.91 (br s, 1H, mannosyl C²H), 6.03 (dd, 1H, ³J_{H,H}=9.8, 3.2 Hz, mannosyl C³H), 7.42–7.55 (m, 4H, mannosyl C¹H, 3 \times C_{ph}H), 7.57–7.67 (m, 2H, C_{ph}H); ¹³C NMR (75 MHz, CDCl₃): δ =8.6 (Cp* CH₃), 20.7, 20.78, 20.80, 20.9 (4 \times OC(O)CH₃), 37.8 (N-CH₃), 62.9 (mannosyl C⁶H₂), 66.2 (mannosyl C⁴H), 68.6 (mannosyl C³H), 69.1 (mannosyl C²H), 72.6 (mannosyl C⁵H), 87.2 (mannosyl C¹H), 88.6 (Cp* qt), 127.1, 127.9, 130.2, 132.4 (4 \times C_{ph}), 149.8 (br 2 \times C_{trz}), 169.0, 169.7, 170.0, 170.5 (4 \times OC(O)CH₃).

5 β Man. According to the general procedure, **3 β Man** (0.280 g, 0.49 mmol), Ag₂O (0.058 g, 0.25 mmol), NMe₄Cl (0.054 g, 0.49 mmol) and [IrCl₂Cp*]₂ (0.159 g, 0.19 mmol) were reacted, yielding **5 β Man** (0.270 g, 0.30 mmol, 62%). Anal. calc. for C₃₃H₄₂N₃O₉IrCl₂·2(H₂O) (923.8643 g/mol), C 42.90, H 5.02, N 4.55%. Found C 43.10, H 5.37, N 4.03%; HRMS (ESI⁺) Calculated for C₃₃H₄₂N₃O₉IrCl₂⁺ [M-Cl]⁺ m/z =852.2233. Found m/z =852.2252; ¹H NMR (300 MHz, CDCl₃): δ =1.41 (s, 15H, Cp*), 2.04, 2.09, 2.25 (3 \times s, 3H, OC(O)CH₃), 3.75 (s, 3H, N-CH₃), 4.16–4.40 (m, 3H, mannosyl C⁶H₂, C⁵H), 5.14–5.28 (m, 1H, mannosyl C²H), 5.47 (t, 1H, ³J_{H,H}=9.9 Hz, mannosyl C⁴H), 5.66 (br s, 1H, mannosyl C²H), 7.40–7.51 (m, 3H, C_{ph}H), 7.56 (br d, 1H, ³J_{H,H}=0.6 Hz, mannosyl C¹H), 7.76 (br s, C_{ph}H); ¹³C NMR (75 MHz, CDCl₃): δ =8.8 (Cp* CH₃), 20.6, 20.8, 20.97, 21.04 (4 \times OC(O)CH₃), 37.8 (N-CH₃), 62.3 (mannosyl C⁶H₂), 65.6 (mannosyl C⁴H), 69.4 (mannosyl C²H), 71.7 (mannosyl C³H), 75.5 (mannosyl C⁵H), 85.6 (mannosyl C¹H), 88.8 (Cp* qt), 127.1, 128.2, 130.2, 132.8 (4 \times C_{ph}), 148.3 (C_{trz}-Ir), 149.3 (C_{trz}-Ph), 169.75, 169.82, 169.9, 170.9 (4 \times C=O).

6 β Glc. According to the general procedure, **4 β Glc** (0.845 g, 1.36 mmol), Ag₂O (0.160 g, 0.69 mmol), NMe₄Cl (0.149 g, 1.36 mmol) and [IrCl₂Cp*]₂ (0.519 g, 0.65 mmol) were reacted, yielding **6 β Glc**

(0.412 g, 0.66 mmol, 48%). Anal. calc. for $C_{35}H_{46}N_3O_{10}IrCl_2 \cdot 2(H_2O)$ (967.917 g/mol), C 43.43, H 5.21, N 4.34%. Found C 43.73, H 5.30, N 3.79%; HRMS (ESI+) Calculated for $C_{35}H_{46}N_3O_{10}IrCl_2^+ [M-Cl]^+$ $m/z = 896.2495$. Found $m/z = 896.2518$; 1H NMR (300 MHz, $CDCl_3$): $\delta = 1.40$ (s, 15H, Cp^*CH_3), 2.00, 2.03, 2.05, 2.09 (4 \times s, 3H, $OC(O)CH_3$), 3.70–3.83 (m, 4H, $N-CH_3$ and C^5H), 4.14 (dd, 1H, $^3J_{H,H} = 2.4$ Hz, $^2J_{H,H} = 12.3$ Hz, glucosyl C^6HH), 4.22–4.50 (m, 3H, glucosyl C^6HH and ethylene CH_2), 4.71 (br s, 1H, glucosyl C^1H), 4.83–5.16 (m, 4H, glucosyl C^2H , C^4H , and ethylene CH_2), 5.21 (t, 1H, $^3J_{H,H} = 9.4$ Hz, glucosyl C^3H), 7.35–7.52 (m, 3H, $C_{Ph}H$), 7.64–7.75 (m, 2H, $C_{Ph}H$); ^{13}C NMR (75 MHz, $CDCl_3$): $\delta = 8.8$ (Cp^*CH_3), 20.6, 20.8, 20.9 (4 \times $OC(O)CH_3$), 37.1 ($N-CH_3$), 61.9 (CH_2), 62.1 (CH_2), 68.2 (glucosyl C^3H), 68.5 (CH_2), 71.4 (glucosyl C^2H), 71.8 (glucosyl C^5H), 72.9 (glucosyl C^4H), 88.2 (Cp^*qt), 100.4 (glucosyl C^1H), 127.6, 127.9, 129.9, 132.6 (4 \times C_{Ph}), 146.6 (C_{trz-Ir}), 149.0 (C_{trz-Ph}), 169.3, 169.6, 170.2, 170.6 (4 \times $C=O$).

6 β Gal. According to the general procedure, **4 β Gal** (0.500 g, 0.80 mmol), Ag_2O (0.093 g, 0.40 mmol), NMe_4Cl (0.087 g, 0.80 mmol) and $[IrCl_2Cp^*]_2$ (0.236 g, 0.30 mmol) were reacted, yielding **6 β Gal** (0.270 g, 0.28 mmol, 36%). Anal. calc. for $C_{35}H_{46}N_3O_{10}IrCl_2 \cdot (H_2O)$ (949.902 g/mol), C 44.26, H 5.09, N 4.42%. Found C 44.17, H 5.14, N 3.89%; HRMS (ESI+) Calculated for $C_{35}H_{46}N_3O_{10}IrCl_2^+ [M-Cl]^+$ $m/z = 896.2495$. Found $m/z = 896.2469$; 1H NMR (300 MHz, $CDCl_3$): $\delta = 1.41$ (s, 15H, Cp^*CH_3), 1.98, 2.06, 2.07, 2.13 (4 \times s, 3H, $OC(O)CH_3$), 3.74 (s, $N-CH_3$), 3.97 (t, 1H, $^3J_{H,H} = 6.7$ Hz, galactosyl C^5H), 4.14 (d, 2H, $J = 6.7$ Hz, galactosyl C^6H_2), 4.28–4.42 (m, 2H, ethylene CH_2), 4.69 (br d, 1H, galactosyl C^1H), 4.76–5.23 (br m, 4H, ethylene CH_2 (broad) and galactosyl C^2H , C^4H), 5.41 (dd, 1H, $J = 3.3$, 1.1 Hz, galactosyl C^3H), 7.39–7.50 (m, 3H, $C_{Ph}H$), 7.63–7.78 (m, 2H, $C_{Ph}H$); ^{13}C NMR (75 MHz, $CDCl_3$): $\delta = 8.8$ (Cp^*CH_3), 20.6, 20.7, 20.8, 21.0 (4 \times $OC(O)CH_3$), 37.1 ($N-CH_3$), 61.1 (galactosyl C^6H_2), 67.0 (galactosyl C^4H), 68.4 (ethylene CH_2), 68.9 (galactosyl C^2H), 70.7 (galactosyl C^3H), 70.9 (galactosyl C^5H), 88.2 (Cp^*qt), 100.8 (galactosyl C^1H), 127.6, 127.9, 129.9, 132.6 (4 \times C_{Ph}), 146.7 (C_{trz-Ir}), 149.0 (C_{trz-Ph}), 169.4, 170.08, 170.12, 170.4 (4 \times $C=O$).

6 α Man. According to the general procedure, **4 α Man** (0.500 g, 0.80 mmol), Ag_2O (0.093 g, 0.40 mmol), NMe_4Cl (0.087 g, 0.80 mmol) and $[IrCl_2Cp^*]_2$ (0.236 g, 0.30 mmol) were reacted, yielding **6 α Man** (0.220 g, 0.23 mmol, 30%). Anal. calc. for $C_{35}H_{46}N_3O_{10}IrCl_2 \cdot (CH_2Cl_2) \cdot 0.5((CH_3)_2CO)$ (961.927 g/mol), C 46.20, H 5.89, N 4.37%. Found C 46.44, H 5.14, N 3.85%; HRMS (ESI+) Calculated for $C_{35}H_{46}N_3O_{10}IrCl_2^+ [M-Cl]^+$ $m/z = 896.2495$. Found $m/z = 896.2481$; 1H NMR (300 MHz, $CDCl_3$): $\delta = 1.42$ (s, 15H, Cp^*CH_3), 1.99, 2.04, 2.13, 2.17 (4 \times s, 3H, $OC(O)CH_3$), 3.77 (s, 3H, $N-CH_3$), 4.00–4.11 (m, 1H, mannosyl C^5H), 4.11–4.44 (m, 4H, ethylene CH_2 and mannosyl C^6H_2), 4.84 (br s, 1H, mannosyl C^1H), 4.93–5.16 (m, 2H, ethylene CH_2), 5.18 (br s, 1H, mannosyl C^2H), 5.21–5.32 (m, 2H, mannosyl C^3H , C^4H), 7.40–7.51 (m, 3H, $C_{Ph}H$), 7.70–7.86 (m, 2H, $C_{Ph}H$); ^{13}C NMR (75 MHz, $CDCl_3$): $\delta = 8.9$ (Cp^*CH_3), 20.73, 20.75, 20.9, 21.0 (4 \times $OC(O)CH_3$), 37.2 ($N-CH_3$), 54.0 (ethylene CH_2), 62.4 (mannosyl C^6H_2), 66.1 (ethylene CH_2), 66.5 (mannosyl C^2H), 68.9 (mannosyl C^5H), 69.3 (mannosyl C^3H), 88.2 (Cp^*qt), 100.0 (mannosyl C^1H), 127.5, 127.9, 129.8, 132.7 (4 \times C_{Ph}), 146.9 (C_{trz-Ir}), 149.2 (C_{trz-Ph}), 169.6, 169.9, 170.3, 170.8 (4 \times $C=O$).

General synthesis of deprotected iridium complexes. The relevant protected iridium complex **5/6** (0.1 mmol) was dissolved in methanolic hydrochloric acid (0.5 M, 2.5 mL) and stood at room temperature overnight. The solution was cooled to $-20^\circ C$ and any precipitate filtered. To the filtrate, copious Et_2O was added and the suspension stored at $-20^\circ C$ for 1 hour. The product was collected as a pale yellow or orange solid upon filtration.

7 α Man. According to the general procedure, protected complex **5 α Man** (0.100 g, 0.11 mmol) was reacted with methanolic hydrochloric acid (0.5 M, 2.5 mL), yielding **7 α Man** (0.052 g,

0.07 mmol, 64%). Anal. calc. for $C_{25}H_{34}N_3O_5IrCl_2 \cdot 2.5(H_2O)$ (784.722 g/mol), C 39.27, H 5.14, N 5.49%. Found C 39.70, H 5.67, N 5.42%; HRMS (ESI+) Calculated for $C_{25}H_{34}N_3O_5IrCl_2^+ [M-Cl]^+$ $m/z = 684.1811$. Found $m/z = 684.1793$; 1H NMR (300 MHz, CD_3OD): $\delta = 1.44$ (s, 15H, Cp^*CH_3), 3.66–4.01 (m, 7H, $N-CH_3$, mannosyl C^6H_2 , C^5H , C^4H), 4.26 (br s, 1H, mannosyl C^2H), 4.37 (br s, 1H, mannosyl C^3H), 6.66 (br s, 1H, mannosyl C^1H), 7.41–7.56 (m, 3H, $C_{Ph}H$), 7.60–7.73 (m, 2H, $C_{Ph}H$); ^{13}C NMR (75 Hz, CD_3OD): $\delta = 7.6$ (Cp^*CH_3), 36.8 ($N-CH_3$), 61.8 (mannosyl C^6H_2), 68.3, 71.0, 71.0, 77.7 (5 \times mannosyl CH), 88.8 (Cp^*qt), 89.5 (mannosyl C^1H), 127.6, 127.7, 129.6, 132.2 (4 \times C_{Ph}), 146.6 (C_{trz-Ir}), 148.2 (C_{trz-Ph}).

7 β Man. According to the general procedure, protected complex **5 β Man** (0.170 g, 0.19 mmol) was reacted with methanolic hydrochloric acid (0.5 M, 2.5 mL), yielding **7 β Man** (0.095 g, 0.13 mmol, 68%). Anal. calc. for $C_{25}H_{34}N_3O_5IrCl_2 \cdot (H_2O)$ (737.700 g/mol), C 40.70, H 4.92, N 5.70%. Found C 40.65, H 5.12, N 5.43%; HRMS (ESI+) Calculated for $C_{25}H_{34}N_3O_5IrCl_2^+ [M-Cl]^+$ $m/z = 684.1811$. Found $m/z = 684.1822$; 1H NMR (300 MHz, CD_3OD): $\delta = 1.32$ (s, 15H, Cp^*CH_3), 3.61–3.82 (m, 4H, mannosyl C^5H , C^4H , C^3H , C^6HH), 4.00 (app d, 1H, $^3J_{H,H} = 11.3$ Hz, mannosyl C^6HH), 4.09 (s, 3H, $N-CH_3$), 4.27 (br s, 1H, mannosyl C^2H), 6.03 (br s, 1H, mannosyl C^1H), 7.49–7.66 (m, 3H, $C_{Ph}H$), 7.82–7.97 (m, 2H, $C_{Ph}H$); ^{13}C NMR (75 MHz, CD_3OD): $\delta = 7.8$ (Cp^*CH_3), 37.0 ($N-CH_3$), 61.3 (mannosyl C^6H_2), 67.3 (mannosyl C^4H), 71.0 (mannosyl C^2H), 73.0 (mannosyl C^3H), 81.4 (mannosyl C^5H), 86.9 (mannosyl C^1H), 89.0 (Cp^*qt), 127.0, 128.7, 130.3, 131.7 (4 \times C_{Ph}), 146.2 (C_{trz-Ir}), 146.9 (C_{trz-Ph}).

8 β Glc. According to the general procedure, protected complex **6 β Glc** (0.250 g, 0.27 mmol) was reacted with methanolic hydrochloric acid (0.5 M, 2.5 mL) yielded **8 β Glc** (0.042 g, 0.06 mmol, 22%). Anal. calc. for $C_{27}H_{38}N_3O_6IrCl_2 \cdot (H_2O)$ (781.753 g/mol), C 41.48, H 5.16, N 5.38%. Found C 41.72, H 5.54, N 5.09%; HRMS (ESI+) Calculated for $C_{27}H_{38}N_3O_6IrCl_2^+ [M-Cl]^+$ $m/z = 728.2078$. Found $m/z = 728.2037$; 1H NMR (300 MHz, CD_3OD): $\delta = 1.41$ (s, 15H, Cp^*CH_3), 3.18 (t, 1H, $^3J_{H,H} = 8.3$ Hz, glucosyl C^2H), 3.24–3.41 (m [overlaps with CH_3OH residual peak], 3H, glucosyl C^4H , C^2H , C^3H), 3.68 (dd, 1H, $^3J_{H,H} = 5.1$ Hz, $^2J_{H,H} = 11.9$ Hz, glucosyl C^6HH), 3.75–3.99 (m, 4H, $N-CH_3$ and glucosyl C^6HH), 4.25 (br s, 1H, ethylene CHH), 4.34–4.54 (m, 2H, ethylene CHH and glucosyl C^1H ($^3J_{H,H} = 7.80$)), 5.00 (br s [overlaps with H_2O resonance], 2H, ethylene CH_2), 7.40–7.53 (m, 3H, $C_{Ph}H$), 7.64–7.76 (m, 2H, $C_{Ph}H$); ^{13}C NMR (75 MHz, CD_3OD): $\delta = 7.7$ (Cp^*CH_3), 36.4 ($N-CH_3$), 53.7 (ethylene CH_2), 61.3 (glucosyl C^6H_2), 67.7 (ethylene CH_2), 70.2 (glucosyl C^4H), 73.6 (glucosyl C^3H), 76.7 (glucosyl C^2H), 76.9 (glucosyl C^5H), 88.5 (Cp^*qt), 103.1 (glucosyl C^1H), 127.5, 127.9, 129.5, 132.4 (4 \times C_{Ph}), 145.9 (C_{trz-Ir} [determined by HMBC]), 148.1 (C_{trz-Ph}).

8 β Gal. According to the general procedure, protected complex **6 β Gal** (0.140 g, 0.15 mmol) was reacted with methanolic hydrochloric acid (0.5 M, 2.5 mL) yielded **8 β Gal** (0.053 g, 0.69 mmol, 46%). Anal. calc. for $C_{27}H_{38}N_3O_6IrCl_2 \cdot 1.5(H_2O)$ (790.761 g/mol), C 41.01, H 5.23, N 5.31%. Found C 40.82, H 5.74, N 5.16%; HRMS (ESI+) Calculated for $C_{27}H_{38}N_3O_6IrCl_2^+ [M-Cl]^+$ $m/z = 728.2078$. Found $m/z = 728.2071$; 1H NMR (300 MHz, CD_3OD): $\delta = 1.42$ (s, 15H, Cp^*CH_3), 3.41–3.61 (m, 3H, galactosyl C^5H , C^2H , C^3H), 3.69–3.91 (m, 6H, galactosyl C^6H_2 , Gal C^4H , $N-CH_3$), 4.24 (br s, 1H, ethylene CHH), 4.37 (d, 1H, $^3J_{H,H} = 6.9$ Hz, galactosyl C^1H), 4.49 (br s, 1H, ethylene CHH), 4.91–5.06 (m [overlaps with H_2O resonance], 2H, ethylene CH_2), 7.39–7.44 (m, 3H, $C_{Ph}H$), 7.63–7.72 (m, 2H, $C_{Ph}H$); ^{13}C NMR (75 MHz, CD_3OD): $\delta = 7.8$ (Cp^*CH_3), 36.4 ($N-CH_3$), 53.7 (ethylene CH_2), 61.1 (galactosyl C^6H_2), 67.8 (ethylene CH_2), 68.9 (galactosyl C^4H), 70.9 (galactosyl C^2H), 73.8 (galactosyl C^3H), 75.3 (galactosyl C^5H), 88.5 (Cp^*qt), 103.8 (galactosyl C^1H), 127.5, 127.9, 129.5, 132.4 (4 \times C_{Ph}), 145.6 (C_{trz-Ir}), 148.1 (C_{trz-Ph}).

8 α Man. Yield = 11%. Anal. calc. for $C_{27}H_{38}N_3O_6IrCl_2 \cdot 2.5(H_2O)$ (808.776 g/mol), C 40.10, H 5.36, N 5.20%. Found C 40.07, H 5.84, N

5.32%; HRMS (ESI+) Calculated for $C_{27}H_{38}N_3O_5IrCl^+$ $[M-Cl]^+$ $m/z = 728.2078$. Found $m/z = 728.2085$; 1H NMR (300 MHz, CD_3OD): $\delta = 1.41$ (s, 15H, Cp^*CH_3), 3.43–3.56 (m, 1H, mannosyl C^5H), 3.56–3.67 (m, 2H, mannosyl C^3H , C^4H), 3.68–3.80 (m, 2H, mannosyl C^2H , C^6HH), 3.81–3.94 (m, 4H, $N-CH_3$, mannosyl C^6HH), 3.93–4.17 (br m, 1H, ethylene CHH), 4.43 (br s, 1H, ethylene CHH), 4.82–5.07 (m [overlaps with H_2O resonance], 3H, mannosyl C^1H and ethylene CH_2), 7.36–7.58 (m, 3H, $C_{ph}H$), 7.59–7.76 (m, 2H, $C_{ph}H$); ^{13}C NMR (75 MHz, CD_3OD) δ 7.7 (Cp^*CH_3), 36.5 ($N-CH_3$), 53.8 (ethylene CH_2), 61.6 (mannosyl C^6H_2), 65.5 (br, ethylene CH_2), 67.0 (mannosyl C^4H), 70.5 (mannosyl C^3H), 71.2 (mannosyl C^2H), 73.7 (mannosyl C^5H), 88.4 (Cp^*qt), 100.4 (mannosyl C^1H), 127.5, 127.8, 129.5, 132.5 ($4 \times C_{ph}$), 145.6 ($C_{tz}-Ir$ [determined by HMBC]), 148.3 ($C_{tz}-Ph$ [determined by HMBC]).

Supporting Information

Supporting Information consisting of supplementary experimental details, crystallographic data, refinement details and further structural analysis, catalytic data, NMR spectra of new compounds, chiral gas chromatograms for *ee* determination, and enzyme inhibition data. CCDC 2142839, 2142842–2142843.

Acknowledgements

We are very grateful to Dr Matteo Planchestainer and Dr René Pretorius for useful discussions. We thank Mr Konrad Uhlmann, Mr Stefan Weissen, and Dr Julien Furrer for technical assistance. This work was financially supported by a Marie Skłodowska-Curie Individual Fellowship (JPB, Grant 749549 'GLYCONHC'), the European Research Council (Grant CoG 615653), the UK EPSRCs (LD, Grant EP/L015633/1) and a Royal Society of Chemistry Researcher Mobility Grant (JPB). We thank the group of Chemical Crystallography of the University of Bern (Prof P. Macchi) for the X-ray structure solution and the Swiss National Science Foundation (R'equip project 206021_128724) for co-funding the single crystal X-ray diffractometer at the Departement für Chemie, Biochemie und Pharmazie, Universität Bern. Open access funding provided by Universität Bern.

Conflict of Interest

The authors declare no conflict of interest.

Data Availability Statement

The data that support the findings of this study are available in the supplementary material of this article.

Keywords: aqueous hydrogenation · carbohydrates · iridium · ligand effects · N-heterocyclic carbene

[1] T. Wang, X. Han, F. Zhong, W. Yao, Y. Lu, *Acc. Chem. Res.* **2016**, *49*, 1369–1378.

- [2] X. Liu, S. Dong, L. Lin, X. Feng, *Chin. J. Chem.* **2018**, *36*, 791–797.
 [3] A. S. Henderson, J. F. Bower, M. C. Galan, *Org. Biomol. Chem.* **2016**, *14*, 4008–4017.
 [4] S. Castellón, C. Claver, Y. Díaz, *Chem. Soc. Rev.* **2005**, *34*, 702.
 [5] S. Woodward, M. Diéguez, O. Pàmies, *Coord. Chem. Rev.* **2010**, *254*, 2007–2030.
 [6] M. Diéguez, O. Pàmies, A. Ruiz, S. Castellón, C. Claver, *Tetrahedron: Asymmetry* **2000**, *11*, 4701–4708.
 [7] K. Yonehara, K. Ohe, S. Uemura, *J. Org. Chem.* **1999**, *64*, 9381–9385.
 [8] M. Diéguez, O. Pàmies, A. Ruiz, S. Castellón, C. Claver, *Chem. A Eur. J.* **2001**, *7*, 3086–3094.
 [9] M. Diéguez, J. Mazuela, O. Pàmies, J. J. Verendel, P. G. Andersson, *J. Am. Chem. Soc.* **2008**, *130*, 7208–7209.
 [10] J. Margalef, O. Pàmies, M. Diéguez, *Chem. A Eur. J.* **2017**, *23*, 813–822.
 [11] W. Zhao, V. Ferro, M. V. Baker, *Coord. Chem. Rev.* **2017**, *339*, 1–16.
 [12] K. J. Kilpin, S. Crot, T. Riedel, J. A. Kitchen, P. J. Dyson, *Dalton Trans.* **2014**, *43*, 1443–1448.
 [13] B. K. Keitz, R. H. Grubbs, *Organometallics* **2010**, *29*, 403–408.
 [14] R. Pretorius, J. Olguín, M. Albrecht, *Inorg. Chem.* **2017**, *56*, 12410–12420.
 [15] J.-H. Li, W.-J. Liu, Y.-X. Xie, *J. Org. Chem.* **2005**, *70*, 5409–5412.
 [16] Y. Imanaka, H. Hashimoto, I. Kinoshita, T. Nishioka, *Chem. Lett.* **2014**, *43*, 687–689.
 [17] C. C. Yang, P. S. Lin, F. C. Liu, I. J. B. Lin, G. H. Lee, S. M. Peng, *Organometallics* **2010**, *29*, 5959–5971.
 [18] A. S. Henderson, J. F. Bower, M. C. Galan, *Org. Biomol. Chem.* **2014**, *12*, 9180–9183.
 [19] A. S. Henderson, J. F. Bower, M. C. Galan, *Org. Biomol. Chem.* **2020**, *18*, 3012–3016.
 [20] J. P. Byrne, P. Musembi, M. Albrecht, *Dalton Trans.* **2019**, *48*, 11838–11847.
 [21] A. Fernandes, B. Royo, *ChemCatChem* **2017**, *9*, 3912–3917.
 [22] Y. Wei, D. Xue, Q. Lei, C. Wang, J. Xiao, *Green Chem.* **2013**, *15*, 629–634.
 [23] M. Martínez-Calvo, J. L. Mascareñas, *Coord. Chem. Rev.* **2018**, *359*, 57–79.
 [24] A. L. E. Larsson, B. A. Persson, J. E. Bäckvall, *Angew. Chem. Int. Ed. Engl.* **1997**, *36*, 1211–1212.
 [25] R. M. Haak, F. Berthiol, T. Jerphagnon, A. J. A. Gayet, C. Tarabiono, C. P. Postema, V. Ritleng, M. Pfeffer, D. B. Janssen, A. J. Minnaard, B. L. Feringa, J. G. De Vries, *J. Am. Chem. Soc.* **2008**, *130*, 13508–13509.
 [26] F. G. Mutti, A. Orthaber, J. H. Schrittwieser, J. G. D. Vries, R. Pietschnig, W. Kroutil, *Chem. Commun.* **2010**, *46*, 8046–8048.
 [27] S. Infante-Tadeo, V. Rodríguez-Fanjul, A. Habtemariam, A. M. Pizarro, *Chem. Rev.* **2021**, *12*, 9287–9297.
 [28] R. V. Maaskant, S. Chordia, G. Roelfes, *ChemCatChem* **2021**, *13*, 1607–1613.
 [29] S. Bose, A. H. Ngo, L. H. Do, *J. Am. Chem. Soc.* **2017**, *139*, 8792–8795.
 [30] V. Köhler, Y. M. Wilson, M. Dürrenberger, D. Ghislieri, E. Churakova, T. Quinto, L. Knörr, D. Häussinger, F. Hollmann, N. J. Turner, T. R. Ward, *Nat. Chem.* **2013**, *5*, 93–99.
 [31] F. Schwizer, Y. Okamoto, T. Heinisch, Y. Gu, M. M. Pellizzoni, V. Lebrun, R. Reuter, V. Köhler, J. C. Lewis, T. R. Ward, *Chem. Rev.* **2018**, *118*, 142–231.
 [32] H. M. Key, P. Dydio, D. S. Clark, J. F. Hartwig, *Nature* **2016**, *534*, 534–537.
 [33] L. L. Rossi, A. Basu, *Bioorg. Med. Chem. Lett.* **2005**, *15*, 3596–3599.
 [34] S. Dedola, D. L. Hughes, S. A. Nepogodiev, M. Rejzek, R. A. Field, *Carbohydr. Res.* **2010**, *345*, 1123–1134.
 [35] K. L. Cosgrove, P. V. Bernhardt, B. P. Ross, R. P. McGeary, *Aust. J. Chem.* **2006**, *59*, 473.
 [36] H. Paulsen, Z. Györgydeák, M. Friedmann, *Chem. Ber.* **1974**, *107*, 1568–1578.
 [37] M. Farrell, J. Zhou, P. V. Murphy, *Chem. A Eur. J.* **2013**, *19*, 14836–14851.
 [38] W. Hayes, H. M. Osborn, S. D. Osborne, R. A. Rastall, B. Romagnoli, *Tetrahedron* **2003**, *59*, 7983–7996.
 [39] C. Kieburg, K. Sadalpure, T. K. Lindhorst, *Eur. J. Org. Chem.* **2000**, *2000*, 2035–2040.
 [40] L. Gu, P. G. Luo, H. Wang, M. J. Meziani, Y. Lin, L. M. Veca, L. Cao, F. Lu, X. Wang, R. A. Quinn, W. Wang, P. Zhang, S. Lacher, Y.-P. Sun, *Biomacromolecules* **2008**, *9*, 2408–2418.
 [41] S. Lal, S. Díez-González, *J. Org. Chem.* **2011**, *76*, 2367–2373.
 [42] A. Petronilho, M. Rahman, J. A. Woods, H. Al-Sayyed, H. Müller-Bunz, J. M. Don MacElroy, S. Bernhard, M. Albrecht, *Dalton Trans.* **2012**, *41*, 13074.
 [43] Determined at 278 K (300 MHz). The minimum value of T_1 could not be determined accurately because of the freezing point of water.
 [44] R. H. Crabtree, *Acc. Chem. Res.* **1990**, *23*, 95–101.

- [45] G. E. Dobereiner, A. Nova, N. D. Schley, N. Hazari, S. J. Miller, O. Eisenstein, R. H. Crabtree, *J. Am. Chem. Soc.* **2011**, *133*, 7547–7562.
- [46] K. F. Donnelly, R. Lalrempuia, H. Müller-Bunz, M. Albrecht, *Organometallics* **2012**, *31*, 8414–8419.
- [47] R. Corberán, M. Sanaú, E. Peris, *J. Am. Chem. Soc.* **2006**, *128*, 3974–3979.
- [48] A. Mollar-Cuni, J. P. Byrne, P. Borja, C. Vicent, M. Albrecht, J. A. Mata, *ChemCatChem* **2020**, *12*, 3746–3752.
- [49] S. Ogo, T. Abura, Y. Watanabe, *Organometallics* **2002**, *21*, 2964–2969.
- [50] M. T. Reetz, T. Neugebauer, *Angew. Chem. Int. Ed.* **1999**, *38*, 179–181; *Angew. Chem.* **1999**, *111*, 134–137.
- [51] M. Guitet, P. Zhang, F. Marcelo, C. Tugny, J. Jiménez-Barbero, O. Buriez, C. Amatore, V. Mouriès-Mansuy, J. P. Goddard, L. Fensterbank, Y. Zhang, S. Roland, M. Ménand, M. Sollogoub, *Angew. Chem. Int. Ed.* **2013**, *52*, 7213–7218; *Angew. Chem.* **2013**, *125*, 7354–7359.
- [52] J. F. Moya, C. Rosales, I. Fernández, N. Khiar, *Org. Biomol. Chem.* **2017**, *15*, 5772–5780.
- [53] M. Coll, O. Pàmies, M. Diéguez, *Adv. Synth. Catal.* **2014**, *356*, 2293–2302.
- [54] S. Horn, C. Gandolfi, M. Albrecht, *Eur. J. Inorg. Chem.* **2011**, *2011*, 2863–2868.
- [55] N. Hassan, T. H. Nguyen, M. Intanon, L. D. Kori, B. K. C. Patel, D. Haltrich, C. Divne, T. C. Tan, *Appl. Microbiol. Biotechnol.* **2014**, *99*, 1731–1744.
- [56] Dialysis of GH1 enzyme into buffers in the pH range where 7βGal gave the best yields of 1-phenylethanol (pH 3–5) resulted in irreversible protein precipitation and denaturing.
- [57] S. Mandal, R. Das, P. Gupta, B. Mukhopadhyay, *Tetrahedron Lett.* **2012**, *53*, 3915–3918.
- [58] A. Bernardi, J. Jiménez-Barbero, A. Casnati, C. De Castro, T. Darbre, F. Fieschi, J. Finne, H. Funken, K.-E. Jaeger, M. Lahmann, T. K. Lindhorst, M. Marradi, P. Messner, A. Molinaro, P. V. Murphy, C. Nativi, S. Oscarson, S. Penadés, F. Peri, R. J. Pieters, O. Renaudet, J.-L. Reymond, B. Richichi, J. Rojo, F. Sansone, C. Schäffer, W. B. Turnbull, T. Velasco-Torrijos, S. Vidal, S. Vincent, T. Wennekes, H. Zuilhof, A. Imberty, *Chem. Soc. Rev.* **2013**, *42*, 4709–4727.
- [59] C. White, A. Yates, P. M. Maitlis, D. M. Heinekey, John Wiley & Sons, Ltd, **2007**, pp. 228–234.

Manuscript received: January 19, 2022
Revised manuscript received: February 23, 2022
Accepted manuscript online: February 23, 2022
Version of record online: March 11, 2022